Q4 2022 Results

Supplementary Lead Company overview Financial review Innovation: Pipeline overview 2023 priorities Appendix Innovation: Clinical trials Abbreviations Novartis submission schedule New Molecular Entities: Lead and supplementary indications 2023 iptacopan LNP023 PNH JDQ443 2024 JDQ443 2/3L NSCLC (mono) remibrutinib LOU064 CSU sabatolimab MBG453 HR-MDS PluvictoⓇ AAA617 mCRPC, Pre-taxane tislelizumab VDT482 1L Gastric Cancer tislelizumab VDT482 1L ESCC tislelizumab VDT482 1L Hepatocellular Carcinoma tislelizumab VDT482 1L Nasopharyngeal cancer iptacopan LNP023 C3G iptacopan LNP023 IgAN PluvictoⓇ AAA617 mHSPC tislelizumab VDT482 1L Small Cell Lung Cancer tislelizumab VDT482 Localized ESCC 1. Gyroscope acquisition. 57 Investor Relations | Q4 2022 Results 凹 Cardiovascular Immunology Neuroscience Solid tumors Hematology Non-core TA project 2025 NIS793 1L Pancreatic cancer pelacarsen TQJ230 CVRR-Lp(a) 177 Lu-NeoB AAA603 Multiple Solid Tumors. W gevokizumab VPM087 1st line CRC ianalumab VAY736 2L Immune Thrombocytopenia cipargamin KAE609 Malaria severe ganaplacide KAF156 Malaria uncomplicated iscalimab CFZ533 Sjögren's syndrome ligelizumab QGE031 Food allergy LNA043 Knee osteoarthritis libvatrep SAF312 COSP ≥2026 MIJ821 Acute depression rapcabtagene autoleucel YTB323 High-risk large B-cell lymphoma Y LXE408 Visceral leishmaniasis TNO155 Solid tumors XXB750 Hypertension PPY9881 Geographic atrophy ianalumab VAY736 1L Immune Thrombocytopenia ianalumab VAY736 WAIHA ianalumab VAY736 AIH ianalumab VAY736 Sjögren's syndrome cipargamin KAE609 Malaria uncomplicated до Y ianalumab VAY736 Lupus Nephritis ianalumab VAY736 SLE iptacopan LNP023 aHUS JDQ443 JDQ443 NSCLC (Combo) remibrutinib LOU064 Multiple sclerosis remibrutinib LOU064 Y Sjögren's syndrome sabatolimab MBG453 Unfit AML tislelizumab VDT482 Adj/Neo adj NSCLC tislelizumab VDT482 1L Urothelial Cell Carcinoma U NOVARTIS | Reimagining Medicine

View entire presentation